Portolan Capital Management LLC Has $8.94 Million Stake in Establishment Labs Holdings Inc. (NASDAQ:ESTA)

Portolan Capital Management LLC grew its holdings in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 243.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 193,991 shares of the company’s stock after acquiring an additional 137,458 shares during the period. Portolan Capital Management LLC owned 0.69% of Establishment Labs worth $8,937,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Assenagon Asset Management S.A. acquired a new stake in Establishment Labs during the fourth quarter worth approximately $12,898,000. William Blair Investment Management LLC boosted its holdings in shares of Establishment Labs by 44.1% during the 4th quarter. William Blair Investment Management LLC now owns 812,825 shares of the company’s stock worth $37,447,000 after buying an additional 248,888 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Establishment Labs during the 4th quarter worth approximately $5,494,000. Royce & Associates LP bought a new stake in shares of Establishment Labs in the 4th quarter valued at $4,862,000. Finally, Simplify Asset Management Inc. raised its holdings in shares of Establishment Labs by 197.1% during the fourth quarter. Simplify Asset Management Inc. now owns 64,300 shares of the company’s stock valued at $2,962,000 after purchasing an additional 42,661 shares during the period. 72.91% of the stock is owned by institutional investors.

Establishment Labs Stock Performance

NASDAQ ESTA opened at $30.34 on Monday. The company has a debt-to-equity ratio of 5.94, a quick ratio of 2.29 and a current ratio of 3.62. The company has a market capitalization of $875.19 million, a PE ratio of -11.76 and a beta of 0.77. Establishment Labs Holdings Inc. has a 52-week low of $26.56 and a 52-week high of $60.12. The company has a 50-day simple moving average of $36.44 and a 200 day simple moving average of $40.10.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.98) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.34). Establishment Labs had a negative net margin of 46.13% and a negative return on equity of 184.55%. The firm had revenue of $44.51 million for the quarter, compared to analysts’ expectations of $44.45 million. On average, research analysts predict that Establishment Labs Holdings Inc. will post -2.41 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on ESTA shares. Stephens restated an “overweight” rating and issued a $52.00 target price on shares of Establishment Labs in a report on Thursday, March 6th. Needham & Company LLC assumed coverage on shares of Establishment Labs in a report on Monday. They set a “hold” rating on the stock. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $57.40.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.